Abstract
Introduction: Limitations in tumor staging and the heterogeneous natural evolution of pT1 urothelial bladder carcinoma (UBC) make the choice of treatment challenging. We evaluated if histopathological substaging (pT1a, pT1b, and pT1c) helps predict disease recurrence, progression, and overall survival following transurethral resection of the bladder (TURB). Methods: We included 239 consecutive patients diagnosed with pT1 UBC at TURB in a single institution since 2001. Each sample was interpreted by our specialized uropathologists trained to subclassify pT1 stage. Three groups were distinguished according to the degree of invasion: T1a (up to the muscularis mucosae [MM]), T1b (into the MM), and T1c (beyond the MM). Results: T1 substaging was possible in 217/239 (90%) patients. pT1a, b, and c occurred in 124 (57), 59 (27), and 34 (16%), respectively. The median follow-up was 3.1 years, with a cumulative recurrence rate of 52%, progression rate of 20%, and survival rate of 54%. Recurrence was not significantly associated with tumor substage (p = 0.61). However, the Kaplan-Meier survival analysis showed a significantly higher progression rate among T1b (31) and T1c (26%) tumors than T1a (13%) (log-rank test: p = 0.001) stages. In a multivariable model including gender, age, ASA score, smoking, tumor grade, and presence of carcinoma in situ, T1 substage was the single variable significantly associated with progression-free survival (HR 1.7, p = 0.005). Nineteen patients (9%) needed radical cystectomy; among them, 12/19 (63%) had an invasive tumor. Overall survival was significantly associated with tumor substaging (p = 0.001). Conclusion: Histopathological substaging of pT1 UBC is significantly associated with tumor progression and overall survival and therefore appears to be a useful prognostic tool to counsel patients about treatment options.
References
1.
Lammers
RJ
, Hendriks
JC
, Rodriguez Faba
OR
, Witjes
WP
, Palou
J
, Witjes
JA
. Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
. World J Urol
. 2016 Feb
;34
(2
):173
–80
. .2.
Hautmann
RE
, Volkmer
BG
, Gust
K
. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3)
. World J Urol
. 2009 Jun
;27
(3
):347
–51
. .3.
Klaassen
Z
, Kamat
AM
, Kassouf
W
, Gontero
P
, Villavicencio
H
, Bellmunt
J
, Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations
. Eur Urol
. 2018 Nov
;74
(5
):597
–608
. .4.
Du
J
, Wang
SH
, Yang
Q
, Chen
QQ
, Yao
X
. p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis
. World J Surg Oncol
. 2016 Apr 30
;14
:137
. .5.
Younes
M
, Sussman
J
, True
LD
. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder
. Cancer
. 1990 Aug 1
;66
(3
):543
–8
. .6.
Smits
G
, Schaafsma
E
, Kiemeney
L
, Caris
C
, Debruyne
F
, Witjes
JA
. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression
. Urology
. 1998 Dec
;52
(6
):1009
–4
.7.
Orsola
A
, Trias
I
, Raventós
CX
, Español
I
, Cecchini
L
, Búcar
S
, Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients
. Eur Urol
. 2005 Aug
;48
(2
):231
–8
. .8.
Colombo
R
, Hurle
R
, Moschini
M
, Freschi
M
, Colombo
P
, Colecchia
M
, Feasibility and clinical roles of different substaging systems at first and second transurethral resection in patients with T1 high-grade bladder cancer
. Eur Urol Focus
. 2018 Jan
;4
(1
):87
–93
. .9.
De Marco
V
, Cerruto
MA
, D’Elia
C
, Brunelli
M
, Otte
O
, Minja
A
, Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder
. Mol Clin Oncol
. 2014 Jul
;2
(4
):575
–80
. .10.
Mhawech
P
, Iselin
C
, Pelte
MF
. Value of immunohistochemistry in staging T1 urothelial bladder carcinoma
. Eur Urol
. 2002 Nov
;42
(5
):459
–63
. .11.
Martin-Doyle
W
, Leow
JJ
, Orsola
A
, Chang
SL
, Bellmunt
J
. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients
. J Clin Oncol
. 2015 Feb 20
;33
(6
):643
–50
. .12.
Rouprêt
M
, Seisen
T
, Compérat
E
, Larré
S
, Mazerolles
C
, Gobet
F
, Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French National Multicenter Study with central pathology review
. J Urol
. 2013 Jun
;189
(6
):2069
–76
.13.
Chen
G
, Yang
T
, Shao
Q
, Zhang
M
, Yang
B
, Zhang
P
, Sub-staging-specific differences in recurrence-free, progression-free, and cancer-specific survival for patients with T1 bladder cancer: a systematic review and meta-analysis
. Urol Int
. 2020
;104
(7–8
):580
–6
. .14.
van Rinj
BW
, van der Kwast
TH
, Alkhateeb
SS
, Fleshner
NE
, van Leeders
GJLH
, Bostrom
PJ
, A new and highly prognostic system to discern T1 bladder cancer substage
. Eur Urol
. 2012 Feb
;61
(2
):378
–84
.15.
Chen
L
, Neumann
RM
, Weaver
AL
, Spotts
BE
, Bostwick
DG
. Predicting cancer progression in patients with stage T1 bladder carcinoma
. J Clin Oncol
. 1999 Oct
;17
(10
):3182
–7
.16.
Brimo
F
, Wu
C
, Zeizafoun
N
, Tanguay
S
, Aprikian
A
, Mansure
JJ
, Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion
. Hum Pathol
. 2013 Jan
;44
(1
):95
–102
. .17.
Bol
MG
, Baak
JP
, Buhr-Wildhagen
S
, Kruse
AJ
, Kjellevold
KH
, Janssen
EA
, Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder
. J Urol
. 2003 Apr
;169
(4
):1291
–4
. .18.
Kramer
MW
, Altieri
V
, Hurle
R
, Lusuardi
L
, Merseburger
AS
, Rassweiler
J
, Current evidence of transurethral en-bloc resection of nonmuscle invasive bladder cancer
. Eur Urol Focus
. 2017 Dec
;3
(6
):567
–76
. .19.
Sylvester
RJ
, Brausi
MA
, Kirkels
WJ
, Hoeltl
W
, Calais Da Silva
F
, Powell
PH
, Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder
. Eur Urol
. 2010 May
;57
(5
):766
–73
. .20.
Sylvester
RJ
, van der Meijden
AP
, Lamm
DL
. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials
. J Urol
. 2002 Nov
;168
(5
):1964
–70
. .21.
Moschini
M
, Sharma
V
, Dell’oglio
P
, Cucchiara
V
, Gandaglia
G
, Cantiello
F
, Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy
. BJU Int
. 2016 Apr
;117
(4
):604
–10
. .22.
Kamat
AM
, Gee
JR
, Dinney
CP
, Grossman
HB
, Swanson
DA
, Millikan
RE
, The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma
. J Urol
. 2006 Mar
;175
(3 Pt 1
):881
–5
. .23.
Losa
A
, Hurle
R
, Lembo
A
. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results
. J Urol
. 2000 Jan
;163
(1
):68
–2
. .24.
Turan
T
, Efiloğlu
Ö
, Günaydin
B
, Özkanli
Ş
, Nikerel
E
, Atiş
G
, Comparative differences between T1a/b and T1e/m as substages in T1 urothelial carcinoma of the bladder
. Int Braz J Urol
. 2018 Mar–Apr
;44
(2
):267
–72
. .25.
Damrauer
JS
, Hoadley
KA
, Chism
DD
, Fan
C
, Tiganelli
CJ
, Wobker
SE
, Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
. Proc Natl Acad Sci U S A
. 2014 Feb 25
;111
(8
):3110
–5
. .26.
Choi
W
, Czerniak
B
, Ochoa
A
, Su
X
, Siefker-Radtke
A
, Dinney
C
, Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer
. Nat Rev Urol
. 2014 Jul
;11
(7
):400
–10
. .27.
Guo
CC
, Czerniak
B
. Bladder cancer in the genomic era
. Arch Pathol Lab Med
. 2019 Jun
;143
(6
):695
–704
. .28.
Faivre d’Acier
B
, Celhay
O
, Safsaf
A
, Zairi
A
, Pfister
C
, Soulié
M
, T1 bladder carcinoma: prognostic value of the muscularis mucosae invasion (T1a/T1b). A multicenter study by the French Urological Association (CCAFU)
. Prog Urol
. 2010 Jun
;20
(6
):440
–9
.29.
Patriarca
C
, Hurle
R
, Moschini
M
, Freschi
M
, Colombo
P
, Colecchia
M
, Usefulness of pT1 substaging in papillary urothelial bladder carcinoma
. Diagn Pathol
. 2016 Jan 20
;11
:6
. .30.
Naselli
A
, Hurle
R
, Paparella
S
, Buffi
NM
, Lughezzani
G
, Lista
G
, Role of restaging transurethral resection for T1 non–muscle invasive bladder cancer: a systematic review and meta-analysis
. Euro Urol Focus
. 2018 Jul
;4
(4
):558
–67
.© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
